Eli Lilly (LLY) Return on Equity ROE from the second quarter 2026 to second quarter 2025 and annually, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Eli Lilly And Company  (NYSE: LLY)

Eli Lilly's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Eli Lilly in the second quarter 2026?
Eli Lilly And Company achieved a return on average equity (ROE) of 92.54 % in its second quarter 2026, this is above LLY's average return on equity of 47.63%.
Eli Lilly And Companys equity during the 12 months ending in the second quarter 2026 are valued at $28 billion

ROE decreased relative to the period ending , due to the decline in net income.

Within the Major Pharmaceutical Preparations industry 8 other companies had a higher return on equity. While Return on equity, overall ranking has advanced in the quarter, so far to 91, from total ROE ranking in the first quarter 2026 at 94.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Equity Change 84.64 % 96.87 % 85.93 % 66.55 % -
Y / Y Net Income Change 25.34 % 168.04 % 50.52 % 475.34 % 90.78 %
Net Income (TTM) in Millions 26,711 25,277 20,640 18,412 13,800
Return On Equity (TTM) 92.54 % 101.17 % 97.61 % 101.84 % 87.91 %
LLY's Total Ranking # 91 # 94 # 59 # 61 # 68
Equity (TTM) in Millions 33,879 31,198 26,535 23,851 18,349
Seq. Equity Change 8.59 % 17.57 % 11.25 % 29.98 % 15.79 %
Seq. Net Income Change -4.07 % 11.42 % 18.9 % -1.38 % 105.14 %

Back to LLY Management Effectiveness >> LLY's 5 Years Annual ROE >> Compare LLY ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 9
Sector # 18
Overall # 91

Return On Equity Statistics
High Average Low
287.25 %
47.63 %
-17.66 %
(Dec 31 2019)   (June 30. 2009)





LLY Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Equity in Millions 26,535 14,272 10,864 10,775 9,155
Y / Y Equity Change 85.93 % 31.37 % 0.82 % 17.7 % 57.16 %
Net Income in Millions 20,640 10,590 5,240 6,245 5,582
Y / Y Net Income Change 94.9 % 102.08 % -16.08 % 11.88 % -9.88 %
Return On Equity 77.78 % 74.2 % 48.24 % 57.95 % 60.97 %

Back to LLY Management Effectiveness >> LLY's 5 Years Annual ROE >> Compare LLY ROE to its Competitors




Annual Roe Comment
In 2025 ROE improved to 77.78 % compared to the previous year, due to net income growth.


More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
LLY's' Return on Equity at Yahoo Finance
LLY's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for LLY's Competitors
Subscribers only: Roe for Eli Lilly's Suppliers
Subscribers only: Return On Equity for LLY's Customers




Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector ROE
Actinium Pharmaceuticals Inc  213.46 %
Halozyme Therapeutics Inc   180.63 %
Capforce Inc   168.50 %
Aveanna Healthcare Holdings Inc   150.35 %
Liquidia Corporation  149.64 %
Interpace Biosciences Inc   142.98 %
Oncotelic Therapeutics Inc   124.17 %
Fortress Biotech Inc   118.22 %
Medpace Holdings Inc   110.15 %
Pulmatrix Inc   108.83 %
Arbutus Biopharma Corp  106.04 %
Rigel Pharmaceuticals Inc  96.49 %
Exelixis Inc   93.62 %
Alnylam Pharmaceuticals Inc   93.61 %
Eli Lilly And Company  92.54 %
Amgen Inc   89.32 %
Q32 Bio Inc   76.88 %
3m Company  76.55 %
Oramed Pharmaceuticals Inc  73.03 %
Tg Therapeutics Inc   72.30 %
Idexx Laboratories Inc  71.96 %
Elite Pharmaceuticals Inc   71.10 %
Zoetis Inc   68.87 %
Rallybio Corporation  68.56 %
Earth Science Tech Inc   66.17 %
Aurinia Pharmaceuticals Inc   59.00 %
Vaxart Inc   53.04 %
Qhslab Inc   51.21 %
Tenet Healthcare Corp  50.64 %
Nrc Health  48.29 %

Date modified: 2026-09-12T18:39:21+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.